{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:25:32Z","timestamp":1790526332640,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1053\/j.seminhematol.2011.05.001","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T03:34:50Z","timestamp":1311564890000},"page":"214-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Molecular Targeted Approaches in Mantle Cell Lymphoma"],"prefix":"10.1053","volume":"48","author":[{"given":"Marc A.","family":"Weniger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2011.05.001_bib1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/fon.10.189","article-title":"Should there be a standard therapy for mantle cell lymphoma?","volume":"7","author":"Smith","year":"2011","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/asheducation-2009.1.542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma","author":"Dreyling","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib5","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib7","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1182\/blood-2006-08-039859","article-title":"Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival","volume":"109","author":"Wiestner","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib8","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/leu.2008.213","article-title":"Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2","volume":"22","author":"Klier","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","article-title":"Cell cycle kinases as therapeutic targets for cancer","volume":"8","author":"Lapenna","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib10","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1200\/JCO.2009.24.1570","article-title":"Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders","volume":"28","author":"Lin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","article-title":"Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription","volume":"35","author":"Manohar","year":"2011","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib14","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/onc.2009.510","article-title":"AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition","volume":"29","author":"Santo","year":"2010","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib15","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1535-7163.MCT-09-1071","article-title":"AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples","volume":"9","author":"Squires","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib16","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1182\/blood-2006-04-016634","article-title":"Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity","volume":"108","author":"Marzec","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib17","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1158\/0008-5472.CAN-07-6404","article-title":"A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model","volume":"68","author":"Menu","year":"2008","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib19","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib21","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib22","first-page":"3963","article-title":"PILLAR-1: Preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to Bortezomib","volume":"116","author":"O'Connor","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib23","first-page":"2803","article-title":"A multi-center phase II study (SAKK 36\/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"116","author":"Renner","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib25","first-page":"772","article-title":"Dual inhibition of mTORC1\/mTORC2 induces apoptosis of mantle cell lymphoma by preventing rictor mediated AKTS473 phosphorylation by potentiating AKT2-PHLPP1 association","volume":"116","author":"Gupta","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib26","first-page":"3242","article-title":"Targeted inhibition of mTORC1 and mTORC2 by the active-site mTOR inhibitors, PP-242 and OSI-027, has cytotoxic effects in T-cell acute lymphoblastic leukemia","volume":"116","author":"Evangelisti","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib27","first-page":"778","article-title":"Targeting mTORC1\/2 by a mTOR kinase inhibitor (PP242) induces apoptosis in AML cells under conditions mimicking bone marrow microenvironment","volume":"116","author":"Zeng","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11912-009-0016-4","article-title":"Perifosine: update on a novel Akt inhibitor","volume":"11","author":"Gills","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib30","first-page":"1842","article-title":"Preclinical and interim results of a phase II trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"116","author":"Friedman","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib31","first-page":"436","article-title":"Genomic and pathway connectivity analyses identify novel strategies to overcome mTOR inhibitor resistance in DLBCL","volume":"116","author":"Petrich","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib32","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1517\/13543784.2010.520701","article-title":"Akt inhibitors in clinical development for the treatment of cancer","volume":"19","author":"Pal","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib33","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib35","first-page":"1777","article-title":"Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"116","author":"Kahl","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib36","first-page":"1783","article-title":"Phase I study of novel prodrug dual PI3K\/mTOR inhibitor SF1126 in B-cell malignancies","volume":"116","author":"Garlich","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib37","first-page":"964","article-title":"The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed\/refractory B-cell malignancies: results from a phase I study","volume":"116","author":"Fowler","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib39","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.06247.x","article-title":"The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9","volume":"135","author":"Georgakis","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.2174\/156802609789895728","article-title":"Update on Hsp90 inhibitors in clinical trial","volume":"9","author":"Kim","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib41","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2010-04-278853","article-title":"The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP\/Grp78","volume":"117","author":"Roue","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib42","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2010.08265.x","article-title":"Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib43","first-page":"1466","article-title":"STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer","volume":"11","author":"Wang","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib44","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib45","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Perez-Galan","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib47","doi-asserted-by":"crossref","first-page":"727a","DOI":"10.1182\/blood.V114.22.727.727","article-title":"NRF2 at the interface of oxidative and endoplasmic reticulum stress pathways is a critical integrator of bortezomib response in mantle cell lymphoma in vitro and in vivo","volume":"114","author":"Weniger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib48","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1073\/pnas.0807611106","article-title":"ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells","volume":"106","author":"Wang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib49","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1078-0432.CCR-09-2882","article-title":"Combination therapy of bortezomib with novel targeted agents: an emerging treatment strategy","volume":"16","author":"Wright","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib51","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib52","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1182\/blood-2009-05-223677","article-title":"Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome","volume":"114","author":"Parlati","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib53","first-page":"2657","article-title":"Non-proteasomal targets of proteasome inhibitors bortezomib and carfilzomib","volume":"112","author":"Arastu-Kapur","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib54","first-page":"985","article-title":"Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"116","author":"diCapua Siegel","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib55","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib57","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm048995+","article-title":"Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor","volume":"48","author":"Macherla","year":"2005","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccr.2005.10.013","article-title":"A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib","volume":"8","author":"Chauhan","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib60","first-page":"1661","article-title":"The VcR-CVAD regimen produces a high complete response rate in untreated mantle cell lymphoma (MCL): first analysis of E1405\u2014a phase II study of VcR-CVAD with maintenance rituximab for MCL","volume":"114","author":"Kahl","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib61","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib62","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1182\/blood-2006-07-034173","article-title":"The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak","volume":"109","author":"Perez-Galan","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib63","first-page":"2569","article-title":"A phase 1 trial of the Pan Bcl-2 family inhibitor obatoclax mesylate (GX15-070) in combination with bortezomib in patients with relapsed\/refractory mantle cell lymphoma","volume":"110","author":"Goy","year":"2007","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib64","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib65","first-page":"2856","article-title":"Treatment with histone deacetylase 6-specific inhibitor WT-161 disrupts hsp90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib","volume":"116","author":"Rao","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib66","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/1535-7163.MCT-09-0988","article-title":"Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells","volume":"9","author":"Rao","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd3321","article-title":"Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets","volume":"10","author":"Bedford","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib68","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1158\/1078-0432.CCR-09-0343","article-title":"Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer","volume":"15","author":"Soucy","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib69","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","article-title":"NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib70","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib71","first-page":"2801","article-title":"Phase 1 dose-escalation study of multiple dosing schedules of the investigational drug MLN4924, a Nedd8-activating enzyme inhibitor, in patients with relapsed and\/or refractory multiple myeloma or lymphoma","volume":"116","author":"Shah","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib72","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2010.08.015","article-title":"MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma","volume":"299","author":"Jin","year":"2010","journal-title":"Cancer Lett"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib73","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma","volume":"15","author":"Tabe","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib74","first-page":"657","volume":"116","author":"Andreeff","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib76","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nrd2658","article-title":"BCL-2 family antagonists for cancer therapy","volume":"7","author":"Lessene","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib77","first-page":"770","article-title":"Rational for the use of a targeted-therapy using ABT-737 in mantle-cell lymphoma","volume":"116","author":"Touzeau","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib78","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib79","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib80","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib81","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood-2008-02-138560","article-title":"AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance","volume":"113","author":"Balakrishnan","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib82","unstructured":"Herishanu Y, Gibellini F, Njuguna N, et al. Activation of CD44, a receptor for extracellular matrix components, protects CLL cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma. In press."},{"key":"10.1053\/j.seminhematol.2011.05.001_bib83","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol Cell"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib84","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/1078-0432.CCR-10-0526","article-title":"Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer","volume":"16","author":"Annunziata","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib85","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","article-title":"The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo","volume":"116","author":"Weston","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CCO.0b013e32833d5954","article-title":"Histone deacetylase inhibitors in lymphoma","volume":"22","author":"Copeland","year":"2010","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib88","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2005-11-026344","article-title":"Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells","volume":"110","author":"Kawamata","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib89","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1349-7006.2009.01360.x","article-title":"Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma","volume":"101","author":"Watanabe","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib90","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1600-0609.2007.00995.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma","volume":"80","author":"Heider","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib92","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1078-0432.CCR-09-1937","article-title":"Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma","volume":"16","author":"Paoluzzi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib93","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tibs.2007.12.002","article-title":"Mining for JAK-STAT mutations in cancer","volume":"33","author":"Constantinescu","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib94","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5858\/2005-129-990-ASOTSP","article-title":"Activation status of the JAK\/STAT3 pathway in mantle cell lymphoma","volume":"129","author":"Yared","year":"2005","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib95","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2009.019745","article-title":"Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma","volume":"95","author":"Baran-Marszak","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib96","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1535-7163.MCT-10-0238","article-title":"Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications","volume":"9","author":"Pham","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib97","first-page":"2830","article-title":"Phase I study of a novel oral JAK-2 inhibitor SB1518 in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes","volume":"116","author":"Younes","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib98","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib99","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2011.05.001_bib100","doi-asserted-by":"crossref","first-page":"1676a","DOI":"10.1182\/blood.V114.22.1676.1676","article-title":"Durable Responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R\/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003)","volume":"114","author":"Witzig","year":"2009","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196311000503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:25Z","timestamp":1758522085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196311000503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0037196311000503"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.05.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Targeted Approaches in Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2011.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}